CRISPR/Cas9 in Gastrointestinal Malignancies

Gastrointestinal (GI) cancers such as colorectal cancer (CRC), gastric cancer (GC), esophageal cancer (EG), pancreatic duct adenocarcinoma (PDAC) or hepatocellular cancer (HCC) belong to the most commonly diagnosed types of cancer and are among the most frequent causes of cancer related death worldw...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	André Jefremow, Markus F. Neurath, Maximilian J. Waldner
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	gastrointestinal cancer CRISPR/cas9 hepatocellular cancer colorectal cancer pancreatic cancer esophageal cancer Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/fc1eb513e2c442008558bd7c5c86998e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fc1eb513e2c442008558bd7c5c86998e
record_format	dspace
spelling	oai:doaj.org-article:fc1eb513e2c442008558bd7c5c86998e2021-12-01T13:53:57ZCRISPR/Cas9 in Gastrointestinal Malignancies2296-634X10.3389/fcell.2021.727217https://doaj.org/article/fc1eb513e2c442008558bd7c5c86998e2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcell.2021.727217/fullhttps://doaj.org/toc/2296-634XGastrointestinal (GI) cancers such as colorectal cancer (CRC), gastric cancer (GC), esophageal cancer (EG), pancreatic duct adenocarcinoma (PDAC) or hepatocellular cancer (HCC) belong to the most commonly diagnosed types of cancer and are among the most frequent causes of cancer related death worldwide. Most types of GI cancer develop in a stepwise fashion with the occurrence of various driver mutations during tumor progression. Understanding the precise function of mutations driving GI cancer development has been regarded as a prerequisite for an improved clinical management of GI malignancies. During recent years, CRISPR/Cas9 has developed into a powerful tool for genome editing in cancer research by knocking in and knocking out even multiple genes at the same time. Within this review, we discuss recent applications for CRISPR/Cas9-based genome editing in GI cancer research including CRC, GC, EG, PDAC and HCC. These applications include functional studies of candidate genes in cancer cell lines or organoids in vitro as well as in murine cancer models in vivo, library screening for the identification of previously unknown driver mutations and even gene therapy of GI cancers.André JefremowMarkus F. NeurathMaximilian J. WaldnerFrontiers Media S.A.articlegastrointestinal cancerCRISPR/cas9hepatocellular cancercolorectal cancerpancreatic canceresophageal cancerBiology (General)QH301-705.5ENFrontiers in Cell and Developmental Biology, Vol 9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	gastrointestinal cancer CRISPR/cas9 hepatocellular cancer colorectal cancer pancreatic cancer esophageal cancer Biology (General) QH301-705.5
spellingShingle	gastrointestinal cancer CRISPR/cas9 hepatocellular cancer colorectal cancer pancreatic cancer esophageal cancer Biology (General) QH301-705.5 André Jefremow Markus F. Neurath Maximilian J. Waldner CRISPR/Cas9 in Gastrointestinal Malignancies
description	Gastrointestinal (GI) cancers such as colorectal cancer (CRC), gastric cancer (GC), esophageal cancer (EG), pancreatic duct adenocarcinoma (PDAC) or hepatocellular cancer (HCC) belong to the most commonly diagnosed types of cancer and are among the most frequent causes of cancer related death worldwide. Most types of GI cancer develop in a stepwise fashion with the occurrence of various driver mutations during tumor progression. Understanding the precise function of mutations driving GI cancer development has been regarded as a prerequisite for an improved clinical management of GI malignancies. During recent years, CRISPR/Cas9 has developed into a powerful tool for genome editing in cancer research by knocking in and knocking out even multiple genes at the same time. Within this review, we discuss recent applications for CRISPR/Cas9-based genome editing in GI cancer research including CRC, GC, EG, PDAC and HCC. These applications include functional studies of candidate genes in cancer cell lines or organoids in vitro as well as in murine cancer models in vivo, library screening for the identification of previously unknown driver mutations and even gene therapy of GI cancers.
format	article
author	André Jefremow Markus F. Neurath Maximilian J. Waldner
author_facet	André Jefremow Markus F. Neurath Maximilian J. Waldner
author_sort	André Jefremow
title	CRISPR/Cas9 in Gastrointestinal Malignancies
title_short	CRISPR/Cas9 in Gastrointestinal Malignancies
title_full	CRISPR/Cas9 in Gastrointestinal Malignancies
title_fullStr	CRISPR/Cas9 in Gastrointestinal Malignancies
title_full_unstemmed	CRISPR/Cas9 in Gastrointestinal Malignancies
title_sort	crispr/cas9 in gastrointestinal malignancies
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/fc1eb513e2c442008558bd7c5c86998e
work_keys_str_mv	AT andrejefremow crisprcas9ingastrointestinalmalignancies AT markusfneurath crisprcas9ingastrointestinalmalignancies AT maximilianjwaldner crisprcas9ingastrointestinalmalignancies
_version_	1718405094576226304

CRISPR/Cas9 in Gastrointestinal Malignancies

Ejemplares similares